The departing CEO Rikard Akhtarzand has agreed with Kenneth Lindqvist, one of the major shareholders of ADDvise, to divest 2,500,000 shares of series A to Kenneth Lindqvist, privately and through companies. The total purchase price for the shares amounts to SEK 37,500,000. The divestment of the shares is subject to approval by the Swedish Inspectorate of Strategic Products (ISP) pursuant to the Screening of Foreign Direct Investments Act (2023:560), and will be completed after the obtaining of such approval.
Upon completion of the transaction, Rikard Akhtarzand’s holdings, privately and through companies, will amount to 120,416 shares of series A and 8,728,493 shares of series B.
The transaction will be reported to the Swedish Financial Supervisory Authority upon completion of the transaction.
For further information, please contact:
Rikard Akhtarzand, CEO
+46 (0) 76-525 90 71
Rikard.Akhtarzand@addvisegroup.se
Important information
This information is such that ADDvise Group AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on July 24, 2024, at 15:50 CEST.
About ADDvise
ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the company's Certified Adviser. More information is available at www.addvisegroup.com.